Cryo Nerve Block Trial

Launched by ST. ANTONIUS HOSPITAL · Feb 28, 2025

Keywords

ClinConnect Summary

The Cryo Nerve Block Trial is studying a technique called intercostal cryo-analgesia (ICCA) to see if it can help patients recover better after minimally invasive lung surgery, such as video-assisted or robot-assisted procedures. This technique uses cold to reduce pain by targeting specific nerves, and the goal is to see if it leads to less pain, shorter recovery times, and reduced need for opioid medications compared to standard pain management methods. The trial will measure recovery using a questionnaire to assess how well patients are doing after their surgery.

Adults aged 18 and older who are scheduled for elective minimally invasive lung surgery may be eligible to participate. Participants will receive either the ICCA treatment along with standard pain relief or standard care alone. While there are potential risks, like nerve damage or numbness, the hope is that ICCA will help improve recovery outcomes. This trial is not yet recruiting, but it aims to provide valuable insights into better pain management after lung surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients are at least 18 years or older.
• • 2. Patients are electively scheduled to undergo minimally invasive (i.e., VATS or RATS) anatomical lung (i.e., pneumonectomy, (bi)lobectomy, or segmentectomy) resection for benign or malignant disease.
• • 3. Proficient understanding of the consequences of enrolment by the patients.
• • 4. Written informed consent by the patient.
• Exclusion Criteria:
• • 1. Patients with reported intolerance or hypersensitivity to the anaesthetic drug used for ICNB.
• • 2. Patients chronically using opioids for reasons not related to the operation (i.e., more than 3 months).
• • 3. Patients with liver failure inhibiting the systematic use of acetaminophen (i.e., paracetamol)
• • 4. Patients with connective tissue disease.
• • 5. Patients with comorbidities or history contra-indicating ICCA.
• • 6. Patients who are pregnant.
• • 7. Participation in other clinical trial(s) that may interfere with the current trial.